Park Ha Biotech Prices $2M Offering at 17% Discount, Signaling Urgent Capital Need
BYAH sits 94% above its 52-week low of $0.93 on elevated volume (41× avg).
Summary
Park Ha Biological Technology priced a $2.0 million registered direct offering at $1.50 per share and pre-funded warrant, a significant discount to its current market price of $1.805. This highly dilutive capital raise represents over 34% of the company's market capitalization. The offering follows the company's recent universal shelf registration and a 6-K filing confirming the pricing. It also comes after the company reported a $24.36 million net loss for FY2025 and announced plans to bypass Nasdaq corporate governance rules. The discounted pricing and substantial dilution underscore the company's urgent need for working capital. The offering is expected to close around June 15, 2026.
At the time of this announcement, BYAH was trading at $1.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.8M. The 52-week trading range was $0.93 to $2,074.50. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.